Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Bellerophon Therapeutics an industry rank of 100 out of 265 based on the ratings given to its competitors.
A number of brokerages recently commented on BLPH. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Friday, September 15th. ValuEngine upgraded shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Bellerophon Therapeutics in a research note on Wednesday, September 6th.
Bellerophon Therapeutics (NASDAQ:BLPH) opened at $2.06 on Friday. Bellerophon Therapeutics has a 12 month low of $0.48 and a 12 month high of $2.44.
TRADEMARK VIOLATION NOTICE: “Zacks: Bellerophon Therapeutics, Inc. (BLPH) Given Consensus Rating of “Strong Buy” by Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/10/zacks-bellerophon-therapeutics-inc-blph-given-consensus-rating-of-strong-buy-by-analysts.html.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.